相关实验视频
Updated: Jan 16, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
906
多层次和多域干预对美国西班牙裔人口的血糖控制的影响
Laura Bianco1, Sofía I Uranga2, Alexander W Rodriguez2
1Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208, USA.
International journal of environmental research and public health
|September 27, 2025
概括
非药物干预措施在2型糖尿病的西班牙裔成年人中适度改善了血糖控制. 多层次,多领域的方法显示出希望,但需要进一步研究社会和环境因素.
科学领域:
- 公共卫生 公共卫生
- 糖尿病管理 糖尿病管理
- 健康差异 在健康上的差异
背景情况:
- 在美国,西班牙裔人口患上2型糖尿病及其并发症的比例很高.
- 解决健康差异需要针对多个层面和领域的干预措施.
- 在这种人群中,有效的血糖控制方法的证据是有限的.
研究的目的:
- 系统地审查非药物干预对糖尿病的西班牙裔个体的血糖控制 (HbA1c) 的影响.
- 根据水平和领域分析干预的有效性.
- 发现西班牙裔人口糖尿病护理方面的研究缺口.
主要方法:
- 来自主要数据库 (PubMed,Scopus,PsycInfo,CINAHL) 的随机试验 (1985-2019) 的系统审查.
- 纳入标准侧重于西班牙裔人口中的HbA1c结果.
- 使用了随机效应元分析和GRADE框架来评估证据质量.
主要成果:
- 包括48项涉及9185名参与者的试验.
- 总体而言,非药物干预措施使HbA1c降低了-0.32% (证据的适度强度).
- 多层次,多领域的干预显示出更大的减少 -0.41% (中等证据强度).
结论:
- 非药物干预措施对患有2型糖尿病的西班牙裔成年人血糖控制提供了适度的好处.
- 多层次,多领域的干预是一个有前途的战略.
- 需要进一步研究解决社区,社会和环境因素的干预措施.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525

